A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma

Trial Profile

A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Planned primary completion date changed from 14 Mar 2017 to 14 Mar 2018.
    • 18 Feb 2017 Results (n=22) assessing bone response to cabozantinib, presented at the 2017 Genitourinary Cancers Symposium
    • 18 Feb 2017 18F-FDG-PET/CT imaging results (n=54) presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top